Replimune Group (REPL) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.05B and a free-cash-flow yield of -14.2%. Nama's AI scorecard rates it Sell, 3.5 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Sell · 3.5/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Middle · +55.3% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-39.8%
How far the last close sits under the highest price of the past five years.
Market cap
$2.05B
Trailing P/E
—
Price / book
10.0
Price / sales
—
FCF yield
-14.2%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.9
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
REPL earnings
Next report: Feb 3, 2027 (Q3 2027, EPS estimate -$0.47).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2027
Oct 28, 2026
-$0.54
-$0.79
+31.6%
$0
Q1 2027
Aug 14, 2026
-$0.72
-$0.77
+6.5%
$0
Q4 2026
Jun 29, 2026
-$0.76
-$0.72
-5.6%
$0
Q3 2026
Feb 3, 2026
-$0.77
-$0.82
+6.1%
$0
REPL analyst price target
Median target $23.50 from 6 analysts, ranging $14.00 – $31.00.
Nama's AI scorecard currently rates Replimune Group Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does REPL report earnings?
Replimune Group's next scheduled report is on Feb 3, 2027. Analysts expect EPS of -$0.47.
What is the REPL price target?
The median analyst price target from 6 analysts is $23.50, with a range of $14.00 – $31.00.
Is REPL Shariah compliant?
Nama's AAOIFI-style screen reads Replimune Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.